The pharmacologic basis of psychotherapeutics: An introduction for psychologists

The Pharmacologic Basis of Psychotherapeutics: An Introduction for Psychologists

Volumn , Issue , 2013, Pages 1-271

  Pagliaro, Louis A ^a,b   Pagliaro, Ann Marie ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Alberta College of Pharmacy   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85074940494     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203761496     Document Type: Book

References (216)

1. Airaudo, C. B., Gayte-Sorbier, A., Bianchi, c., & Verdier, M. (1993). Interactions between six psychotherapeutic drugs and plastic containers. International Journal of Clinical Pharmacology, Therapy and Toxicology, 31, 261-266.
2. Alcohol-medication interactions. (1995, January). National Institute on Alcohol Abuse and Alcoholism, Alcohol Alert, No. 27, PH355, pp. 1-4.
3. Andrews, J. M., & Nemeroff, C. B. (1994). Contemporary management of depression. American Journal of Medicine, 97, 24S-32S.
4. Ascher, J. A., Cole, C. 0., Colin, N., Feighner, P., Ferris, R. M., Ribiger, H., Goldem, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995). Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395-401.
5. Ashton, H. (1994). Guidelines for the rational use of benzodiazepines. When and what to use. Drugs, 48, 25-40.
6. Ashton, H. (1994). The treatment of benzodiazepine dependence. Addiction, 89, 1535-1541.
7. Azorin, J. M. (1995). Long-term treatment of mood disorders in schizophrenia. Acta Psychiatrica Scandinavica, 388, 20-23.
8. Bailey, R. T., Jr., Bonavina, L., Nwakama, P. E., De Meester, T. R., & Cheng, S. C. (1990). Influence of dissolution rate and pH of oral medications on drug-induced esophageal injury. Annals of Pharmacotherapy, 24, 571-573.
9. Baldassano, C. F., Truman, C. 1., Nierenberg, A., Ghaemi, S. N., & Sachs, G. S. (1996). Akathisia: A review and case report following paroxetine treatment. Comprehensive Psychiatry, 37, 122-124.
10. Bapna, J. S. (1989). Education on the concept of essential drugs and rationalized drug use. Clinical Pharmacology & Therapeutics, 45, 217-219.
11. Barden, N., Reul, J. M., & Hoisboer, F. (1995). Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences, l8, 6-11.
12. Beasley, C. M., Jr., Masica, D. N., Heiligenstein, J. H., Wheadon, D. E., & Zerbe, R. L. (1993). Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. Journal of Clinical Psychopharmacology, 13, 312-320.
13. Benet, L. Z., & Pagliaro, L. A. (1986). Pharmacokinetic considerations in drug response. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 118-129). St. Louis, MO: C. V. Mosby.
14. Bhatara, V. S., & Bandettini, F. C. (1993). Possible interaction between sertraline and tranylcypro-mine. Clinical Pharmacy, 12, 222-225.
15. Bhatara, V. S., & Bandettini, F. (1993). Serotonin syndrome and drug interactions [Letter]. Clinical Pharmacology & Therapeuti cs, 53, 230.
16. Biegon, A., & Volkow, N. D. (Eds.). (1995). Sites of drug action in the human brain. Boca Raton, FL: CRC Press.
17. Blaisdell, G. D. (1994). Akathisia: A comprehensive review and treatment summary. Pharmaco-psychiatry, 27, 139-146.
18. Block, L. H. (1983). Drug interactions in the geriatric client. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Pharmacologic aspects of aging (pp. 140-191). St. Louis, MO: C. V. Mosby.
19. Bloomfield, S. S., Cissell, G. B., Mitchell, J., Barden, T. P., Kaiko, R. F., Fitzmartin, R. D., Grandy, R. P., Komorowski, J., & Goldenheim, P. D. (1993). Analgesic efficacy and potency of two oral controlled-release morphine preparations. Clinical Pharmacology and Therapeutics, 53, 469-478.
20. Borison, R. L. (1995). Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Journal of Clinical Psychopharmacology, 15(Suppl. I), 24S-29S.
21. Bostrom-Ezrati, J., Dibble, S., & Rizzuto, C. (1990). Intravenous therapy management: Who will develop insertion site symptoms? Applied Nursing Research, 3, 146-152.
22. Bowden, C. L. (1996). Role of newer medications for bipolar disorder. Journal of Clinical Psychopharmacology, J 6(Suppl. I), 48S-55S.
23. Boyer, W. F., & Blumhardt, C. L. (1992). The safety profile of paroxetine. Journal of Clinical Psychiatry, 53, 61-66.
24. Bristow, M. R. (1993). Changes in myocardial and vascular receptors in heart failure. Journal of the American College of Cardiology, 22(Suppl. A), 61A-71 A.
25. Brodde, O. E. (1993). Beta-adrenoceptors in cardiac disease. Pharmacology & Therapeutics, 60, 405-430.
26. Brosen, K. (1995). Drug interactions and the cytochrome P450 system. The role of cytochrome P450 IA2. Clinical Pharmacokinetics, 29(Suppl. I), 20-25.
27. Brosen, K. (1996). Are pharmacokinetic drug interactions with the SSRIs an issue? International Clinical Psychopharmacology, II (Suppl. I), 23-27.
28. Bmera, E., Legris, M. A., & Kuehn, N. (1990). Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. Journal of Pain and Symptom Management, 5, 218-220.
29. Buchanan, R. W. (1995). Clozapine: Efficacy and safety. Schizophrenia Bulletin, 21, 579-591.
30. Buck, M. L., & Blumer, J. L. (1991). Phenothiazine associated apnea in two siblings. Annals of Pharmacotherapy, 25, 244-247.
31. Butler, S. H. (1986). Analgesics and narcotic antagonists. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 299-324). St. Louis, MO: C. V. Mosby.
32. Caccia, S., & Garattini, S. (1990). Formation of active metabolites of psychotropic drugs: An updated review of their significance. Clinical Pharmacokinetics, 18, 434-459.
33. Cardella, J. F., Fox, P. S., & Lawler, J. B. (1993). Interventional radiologic placement of peripherally inserted central catheters. Journal of Vascular & Interventional Radiology, 4, 653-660.
34. Cohen, M. R., & Davis, N. M. (1992). Free flow associated with electronic infusion devices: An underestimated danger. Hospital Pharmacy, 27, 384-390.
35. Connolly, M. J. (1993). Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacology & Therapeutics, 60, 389-404.
36. Cooper, R., Bloom, F. E., & Roth, R. H. (1996). The biochemical basis of neuropharmacology (7th ed.). New York: Oxford University Press.
37. Corso, D. M., Pucino, F., DeLeo, J. M., Calis, K. A., & Gallelli, J. F. (1992). Development of a questionnaire for detecting potential adverse drug reactions. Annals of Pharmacotherapy, 26, 890-892.
38. Costa, E., & Guidotti, A. (1996). Benzodiazepines on trial: A research strategy for their rehabilitation. Trends in Pharmacological Sciences, 17, 192-200.
39. Davis, M., Matalon, L., Watanabe, M. D., Blake, L., & Metalon, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741-773.
40. Denny, D. F. (1993). Placement and management of long-term central venous access catheter ports. American Journal of Roentgenology, 161, 385-393.
41. DeVane, C. L. (1994). Pharmacokinetics of the newer antidepressants: Clinical relevance. American Journal of Medicine, 97, 13S-23S.
42. De Vane, C. L. (1995). Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. American Journal of Health-System Pharmacy, 52(Suppl. 1), SI5-S18.
43. Devinsky, O., & Pacia, S. V. (1994). Seizures during clozapine therapy. Journal of Clinical Psychiatry, 55(Suppl. B), 153-156.
44. Dewhurst, W. G. (1986). Drugs used to treat affective disorders. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 352-381). St. Louis, MO: C. V. Mosby.
45. Diagnostic and statistical manual of mental disorders (4th ed.). (1994). Washington, DC: American Psychiatric Association.
46. DiPadova, C., Roine, R., Frezza, M., Gentry, R. T., Baraona, E., & Lieber, C. S. (1992). Effects of ranitidine on blood alcohol levels after ethanol ingestion. Journal of the American Medical Association, 267, 83-86.
47. DiSalvo, T. G., & O' Gara, P. T. (1995). Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clinical Cardiology, 18, 285-290.
48. Dockens, R. c., Greene, D. S., & Barbhaiya, R. H. (1996). Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. Journal of Clinical Pharmacology, 36, 160--167.
49. Drug/drug interaction: Fluoxetine/phenytoin. (1994). Drug Evaluations Monitor, 2, 7.
50. Drugs that cause psychiatric symptoms. (1993). Medical Letter on Drugs and Therapeutics, 35, 65-70.
51. Dubovsky, S. L., & Thomas, M. (1996). Tardive dyskinesia associated with fluoxetine. Psychiatric Services, 47, 991-993.
52. Ellingrod, V. L., & Perry, P. 1. (1994). Venlafaxine: A heterocyclic antidepressant. American Journal of Hospital Pharmacy, 51, 3033-3046.
53. Ellingrod, V. L., & Perry, P. J. (1995). Nefazodone: A new antidepressant. American Journal of Health-System Pharmacy, 52, 2799-2812.
54. Ereshefsky, L., Riesenman, C., & Lan, Y. W. (1995). Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clinical Pharmacokinetics, 29(Suppl. 1), 10-18.
55. Estes, W. (1995). The road to tranquillity: The search for selective anti-anxiety agents. Synapse, 21(1), 10--20.
56. Evans, R., Miranda, R. N., Jordan, J., & Krolikowski, F. 1. (1995). Fatal acute pancreatitis caused by valproic acid. American Journal of Forensic Medicine & Pathology, 16, 62-65.
57. Feighner, P. (1994). The role of venlafaxine in rational antidepressant therapy. Journal of Clinical Psychiatry, 55(Suppl. A), 62-68.
58. Fernstrom, M. H. (1995). Drugs that cause weight gain. Obesity Research, 3(Suppl. 4), 435S-439S.
59. Fleischhacker, W. W. (1995). New drugs for the treatment of schizophrenic patients. Acta Psychiatrica Scandinavica, 388(Suppl.), 24-30.
60. Friesen, A. D. (1983). Adverse drug reactions in the geriatric client. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Pharmacologic aspects of aging (pp. 257-293). St Louis, MO: C. V. Mosby.
61. Garcia, B., Zaborras, E., Areas, V., Obeso, G., Jimenez, I., de Juana, P., & Bermejo, T. (1992). Interaction between isoniazid and carbamazepine potentiated by cimetidine [Letter]. Annals of Pharmacotherapy, 26, 841.
62. Geller, L., Gaulin, B. D., & Barreira, P. 1. (1992). A practitioner 's guide to use of psychotropic medication in liquid form. Hospital and Community Psychiatry, 43, 969-971.
63. Generali, A. (1996). Drug-nutrient interactions: New drug update. Drug Newsletter, 15(6), 42-44.
64. Generali, A. (1996). Serotonin syndrome. Drug Newsletter, 15(10), 76-77.
65. Gerlach, L. (1994). Oral versus depot administration in relapse prevention. Acta Psychiatrica Scandinavica, 382(Suppl.), 28-32.
66. Gerlach, L. (1995). Depot neuroleptics in relapse prevention: Advantages and disadvantages. International Clinical Psychopharmacology, 9(Suppl. 5), 17-20.
67. Gibaldi, M. (1992). Drug interactions: Part I. Annals of Pharmacotherapy, 26, 709-713.
68. Gibaldi, M. (1992). Drug interactions: Part II. Annals of Pharmacotherapy, 26, 829-834.
69. Gitlin, M. (1994). Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches. Journal of Clinical Psychiatry, 55, 406-413.
70. Gitlin, M. (1995). Effects of depression and antidepressants on sexual functioning. Bulletin of the Menninger Clinic, 59, 232-248.
71. Givens, B., Oberle, S., & Lander, L. (1993). Taking the jab out of needles. The Canadian Nurse, 89(10), 37-40.
72. Goff, D. c., Henderson, D. c., & Amico, E. (1992). Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. American Journal of Psychiatry, 149, 1189-1194.
73. Gold, P. W., Licinio, L., Wong, M. L., & Chrousos, G. P. (1995). Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of the antidepressant drugs. Annals of the New York Academy of Sciences, 771, 716-729.
74. Goodnick, P. (1994). Pharmacokinetic optimisation of therapy with newer antidepressants. Clinical Pharmacokinetics, 27, 307-330.
75. Graber, M. A., Hoehns, T. B., & Perry, P. (1994). Sertraline-phenelzine drug interaction: A serotonin syndrome reaction. Annals of Pharmacotherapy, 28, 732-735.
76. Graham, D. R., Keldermans, M. M., Klemm, L. W, Semenza, N., & Shafer, M. L. (1991). Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. American Journal of Medicine, 91(3B), 95S-100S.
77. Haggett, R. R., & Gionet, P. 1. (1992). Peripherally inserted central catheters-Review and case reports. Alaska Medicine, 34, 140-141.
78. Hansten, P. D. (1986). Drug interactions. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 170-179). St. Louis, MO: C. V. Mosby.
79. Hansten, P. D. (1995). Pediatric drug interactions. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Problems in pediatric drug therapy (3rd ed., pp. 463-504). Hamilton, IL: Drug Intelligence.
80. Haria, M., Fitton, A., & McTavish, D. (1994). Trazodone: A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs & Aging, 4, 331-355.
81. Harth, Y, & Rapoport, M. (1996). Photosensitivity associated with anti psychotics, antidepressants and anxiolytics. Drug Safety, 14, 252-259.
82. Hedges, c., & Karas, B. S. (1993). Peripherally-inserted central catheters: Challenges for hospital management. Medical Surgical Nursing, 2, 443--450.
83. Hensley, L. R. (1991). Continuous SC morphine for cancer pain. American Journal of Nursing, 98-101.
84. Hirschfeld, R. M. (1994). Guidelines for the long-term treatment of depression. Journal of Clinical Psychiatry, 55(Suppl.), 61-69.
85. Hoener, B. (1986). Drug availability and distribution. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 78-94). St. Louis, MO: C. V. Mosby.
86. Holsboer, F., Grasser, A., Friess, E., & Wiedemann, K. (1994). Steroid effects on central neurons and implications for psychiatric and neurological disorders. Annals of the New York Academy of Sciences, 746, 345-359.
87. Human, S. E., & Nestler, E. J. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153, 151-162.
88. Hunt, N., & Stern, T. A. (1995). The association between intravenous haloperidol and torsade de pointes. Three cases and a literature review. Psychosomatics, 36, 541-549.
89. International classification of diseases (10th ed.). (1993). Geneva: World Health Organization.
90. James, L., Bledsoe, L., & Hadaway, L. C. (1993). A retrospective look at tip location and complications of peripherally inserted central catheter lines. Journal of Intravenous Nursing, 16, 104-109.
91. Janai, H. (1990). Adverse drug reactions: United States experience. Part 1. Pediatric Infectious Disease Journal, 9, S 115-S 116.
92. Janicak, P. G. (1993). The relevance of clinical pharmacokinetics and therapeutic drug monitoring. Anticonvulsant mood stabilizers and anti psychotics. Journal of Clinical Psychiatry, 54(Suppl.), 35-41.
93. Johnson, M. S., Pesko, L. J., Wood, C. F., & Reinders, T. P. (1990). Cost and acceptability of three syringe-pump infusion systems. American Journal of Hospital Pharmacy, 47, 1794-1798.
94. Joyce, T. H. (1993). Topical anesthesia and pain management before venipuncture. Journal of Pediatrics, 22(5, Part 2), S24-S29.
95. Kalow, W. (1993). Pharmacogenetics: Its biologic roots and the medical challenge. Clinical Pharmacology & Therapeutics, 54, 235-241.
96. Kane, J. M., Jeste, D. v., & Barnes, T. R. E. (1992). Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association.
97. Kane, L. M., & Lieberman, J. A. (Eds.). (1992). Adverse effects of psychotropic drugs. New York: Guilford Press.
98. Keck, P. E., Caroff, S. N., & McElroy, S. L. (1995). Neuroleptic malignant syndrome and malignant hyperthermia: End of a controversy? Journal of Neuropsychiatry & Clinical Neurosciences, 7, 135-144.
99. Ketter, T. A., Flockhart, D. A., Post, R. M., Denicoff, K., Pazzaglia, P. J., Marangell, L., George, M. S., & Callahan, A. M. (1995). The emerging role of cytochrome P450 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
100. Kittel, J. F. (1986). Sedative-hypnotics. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 252-283). St. Louis, MO: C. V. Mosby.
101. Koch, K. E. (1990). Use of standardized screening procedures to identify adverse drug reactions. American Journal of Hospital Pharmacy, 47, 1314-1320.
102. Kopala, L. C. (1996). Risperidone for child and adolescent schizophrenia. Child & Adolescent Psychopharmacology News, 1(2), 1-4.
103. Kostowski, W. (1995). Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Polish Journal of Pharmacology, 47, 237-246.
104. Kunovac, L., & Stahl, S. M. (1995). Future directions in anxiolytic pharmacotherapy. Psychiatric Clinics of North America, 18, 895-909.
105. Latimer, P. R. (1995). Tardive dyskinesia: A review. Canadian Journal of Psychiatry, 40(Suppl. 2), S49-S54.
106. Levinson, M. L., Lipsy, R., & Fuller, D. K. (1991). Adverse effects and drug interactions associated with f1uoxetine therapy. Drug Intelligence and Clinical Pharmacy, 25, 657-661.
107. Lindenmayer, P. (1995). New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatrica Scandinavica, 388(Suppl.), 15-19.
108. Logan, M., & Fothergill-Bourbonnais, F. (1990). Continuous subcutaneous infusion of narcotics (CSCI)-Preparing family caregivers for managing chronic pain in the home. Canadian Nurse, 85(4), 31-32.
109. Marder, S. R. (1994). The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psychiatrica Scandinavica, 382(Suppl.), 25-27.
110. Marti-Masso, F., Lopez de Munain, A., & Lopez de Dicastillo, G. (1992). Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Annals of Pharmacotherapy, 26, 429-430.
111. McLean, D. R. (1986). Antiparkinsonian medications and stimulants. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 382-404). St. Louis, MO: C. V. Mosby.
112. McLean, D. R. (1986). Drugs used to treat epilepsy. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 405-432). St. Louis, MO: C. V. Mosby.
113. Medication errors. (1996). Prescriber's Letter, 3(12), 72.
114. Megens, A. A., Awouters, F. H., Schotte, A., Meert, T. F., Dugovic, c., Niemegeers, C. J., & Leysen, E. (1994). Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology, 114, 9-23.
115. Merrell, S. w., Peatross, B. G., Grossman, M. D., Sullivan, J. J., & Harker, W. G. (1994). Peripherally inserted central venous catheters: Low-risk alternatives for ongoing venous access. Western Journal of Medicine, 160(1), 25-30.
116. Meyer, F. P., Troger, U., & Rohl, F.-w. (1996). Pharmacoepidemiology and drug utilization. Clinical Pharmacology & Therapeutics, 60, 347-352.
117. Mitchell, F., & Pawlicki, K. S. (1994). Oral dosage forms that should not be crushed: 1994 revision. Hospital Pharmacy, 29, 666-668, 670-675.
118. Morton, W. A., Sonne, S. c., & Verga, M. A. (1995). Venlafaxine: A structurally unique and novel antidepressant. Annals of Pharmacotherapy, 29, 387-395.
119. Moulin, D. E., Kreeft, J. H., Murray-Parsons, N., & Bouquillon, A. (1991). Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet, 337, 465-468.
120. Mulligan, S. C., Masterson, J. G., Devane, J. G., & Kelly, G. (1990). Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clinical Pharmacology & Therapeutics, 47, 331-337.
121. Murray, M. (1992). P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics, 23, 132-146.
122. Naganuma, H., & Fujii, I. (1994). Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 90, 424-426.
123. Naranjo, C. A., Shear, N. H., & Lanctot, K. L. (1992). Advances in the diagnosis of adverse drug reactions. Journal of Clinical Pharmacology, 32, 897-904.
124. Nemeroff, C. B. (1994). Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry, 55(Suppl.), 3-15.
125. Nemeroff, C. B., DeVane, C. L., & Pollock, B. G. (1996). Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153, 311-320.
126. Nestler, E. (1992). Molecular mechanisms of drug addiction. Journal of Neuroscience, 12, 2439-2450.
127. Neuvonen, P., Pohjola-Sintonen, S., Tacke, U., & Vuori, E. (1993). Five fatal cases of serotonin syndrome after mocIobemide-citalopram or mocIobemide-cIomipramine overdoses [Letter]. Lancet, 342, 1419.
128. Neuvonen, P., Varhe, A., & Olkkola, K. T. (1996). The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clinical Pharmacology & Therapeutics, 60, 326-331.
129. New Wyeth gel filled temazepam capsules. (1990). Pharmaceutical Journal, 244, 593.
130. Nilsson, A., Boman, L., Wallin, B., & Rotstein, A. (1994). The EM LA patch-A new type of local anaesthetic application for dermal analgesia in children. Anaesthesia, 49, 70-72.
131. Nimmo, W. S. (1990). The promise of transdermal drug delivery. British Journal of Anaesthesia, 64, 7-10.
132. Nordin, c., & Bertilsson, L. (1995). Active hydroxymetabolites of antidepressants. Emphasis on E-IO-hydroxy-nortriptyline. Clinical Pharmacokinetics, 28, 26-40.
133. Obesity. (1996). Prescriber's Letter, 3(12), 68.
134. Olkkola, K. T., Backman, J. T., & Neuvonen, P. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology & Therapeutics, 55, 481-485.
135. O' Mara, N. B., & Nahata, M. C. (1995). Drugs excreted in human breast milk. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Problems in pediatric drug therapy (3rd ed., pp. 245-335). Hamilton, IL: Drug Intelligence.
136. Oshika, T. (1995). Ocular adverse effects of neuropsychiatric agents. Drug Safety, 12, 256-263.
137. Owens, D. G. (1996). Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs, 51, 895-930.
138. Pagliaro, A. M. (1985, October). Diet, vitamins, and nutrient interactions with drugs in the elderly. Paper presented at the International Holistic Gerontology Symposium, Ponoka, Alberta, Canada.
139. Pagliaro, A. M. (1995). Administering drugs to infants, children, and adolescents. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Problems in pediatric drug therapy (pp. 1-101). Hamilton, IL: Drug Intelligence.
140. Pagliaro, A. M., & Pagliaro, L. A. (Eds.). (1986). Pharmacologic aspects of nursing. St. Louis, MO: C. V. Mosby.
141. Pagliaro, A. M., & Pagliaro, L. A. (1996). Substance use among children and adolescents: Its nature, extent, and effects from conception to adulthood. New York: John Wiley & Sons.
142. Pagliaro, L. A. (1985, October). Drug interactions in the elderly: Overview and basic principles. Paper presented at the International Holistic Gerontology Symposium, Ponoka, Alberta, Canada.
143. Pagliaro, L. A. (1986). Mechanisms of drug action. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 71-77). St. Louis, MO: C. V. Mosby.
144. Pagliaro, L. A. (1994). Pharmacopsychology updates: Attention-deficitlhyperactivity disorder. Psymposium, 4(3), 14-15.
145. Pagliaro, L. A. (1995). Pharmacopsychology updates: Drugs and sexual (dys)function. Psymposium, 4(6), 20-2l.
146. Pagliaro, L. A. (1995). Pharmacopsychology updates: Psychotropic teratogens. Psymposium, 5(1), 18-19.
147. Pagliaro, L. A. (1995). The straight dope: A consideration of substance-induced disorders. Psynopsis, 17, 14.
148. Pagliaro, L. A. (1996). Pharmacopsychology updates: Drug prescription privileges for psychologists. Psymposium, 5(4), 11-12.
149. Pagliaro, L. A. (1996). Should Canadian psychologists follow the APA trend and seek prescription privileges?: Of course they should!-An invited critical commentary of Dozois and Dobson. Canadian Psychology, 36, 305-312.
150. Pagliaro, L. A., & Benet, L. Z. (1975). Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. Journal of Pharmacokinetics and Biopharmaceutics, 3, 333-383.
151. Pagliaro, L. A., & Locock, R. A. (1992). Nutritional products. In Self-medication: Reference for health professionals (4th ed.). Ottawa: Canadian Pharmaceutical Association.
152. Pagliaro, L. A., & Pagliaro, A. M. (Eds.). (1983). Pharmacologic aspects of aging. St. Louis, MO: C. V. Mosby.
153. Pagliaro, L. A., & Pagliaro, A. M. (1986). Adverse drug reaction index. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 1727-1745). St. Louis, MO: C. V. Mosby.
154. Pagliaro, L. A., & Pagliaro, A. M. (1986). Age-dependent drug selection and response. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 130-139). St. Louis, MO: C. V. Mosby.
155. Pagliaro, L. A., & Pagliaro, A. M. (1986). Drugs used to treat psychotic disorders. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 325-351). St. Louis, MO: C. V. Mosby.
156. Pagliaro, L. A., & Pagliaro, A. M. (1992). Alcohol metabolism in a native patient [Letter]. Canadian Medical Association lournal, 146, 2141.
157. Pagliaro, L. A., & Pagliaro, A. M. (1992). Drug induced aggression. The Medical Psychotherapist, 8(2-3), 9.
158. Pagliaro, L. A., & Pagliaro, A. M. (1992). Pharmacopsychology as distinct from psychopharmacology: The initial results of a historical and philosophical inquiry [Abstract]. Canadian Psychology, 33, 437.
159. Pagliaro, L. A., & Pagliaro, A. M. (1993). Carbamazepine-induced Stevens-Johnson syndrome. Hospital and Community Psychiatry, 44, 999-1000.
160. Pagliaro, L. A., & Pagliaro, A. M. (1995). Abuse potential of the antidepressants: Does it exist? CNS Drugs, 4(4), 1-6.
161. Pagliaro, L. A., & Pagliaro, A. M. (1995). Alcoholic cognitive impainnent and reliability of eyewitness testimony: A forensic case report. The Medical Psychotherapist, 11(1), 9-10.
162. Pagliaro, L. A., & Pagliaro, A. M. (1995). Drug prescription privileges for Canadian psychologists: Attainable and necessary. Canadian Clinical Psychologist, 5(3), 2-5.
163. Pagliaro, L. A., & Pagliaro, A. M. (Eds.). (1995). Problems in pediatric drug therapy (3rd ed.). Hamilton, IL: Drug Intelligence.
164. Pagliaro, L. A., & Pagliaro, A. M. (1998). Psychologists' psychotropic desk reference. Washington, DC: Taylor & Francis.
165. Pagliaro, L. A., & Pagliaro, A. M. (in press). Clinical psychopharmacotherapeuticsfor psychologists. Washington, DC: Taylor & Francis.
166. Perry, P. J. (1995). Clinical use of the newer antipsychotic drugs. American lournal of Health System Pharmacy, 52(Suppl. I), S9-S 14.
167. Perry, P. J., Zeilmann, c., & Arndt, S. (1994). Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. lournal of Clinical Psychopharmacology, 14, 230-240.
168. Perucca, E., Gatti, G., & Spina, E. (1994). Clinical phannacokinetics of fluvoxamine. Clinical Pharmacokinetics, 27, 175-190.
169. Petursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction, 89, 1455-1459.
170. Popli, A. P., Kando, J. C., Pillay, S. S., Tohen, M., & Cole, O. (1995). Occurrence of seizures related to psychotropic medication among psychiatric inpatients. Psychiatric Services, 46, 486.
171. Prosser, T. R., & Kamysz, P. L. (1990). Multidisciplinary adverse drug reaction surveillance program. American lournal of Hospital Pharmacy, 47, 1334-1339.
172. Reiss, R. A., Haas, C. E., Karki, S. D., Gumbiner, B., Welle, S. L., & Carson, S. W. (1994). Lithium phannacokinetics in the obese. Clinical Pharmacological Therapeutics, 55, 392-398.
173. Reynolds, G. P. (1994). Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatrica Scandinavica, 380, 36-40.
174. Ritschel, W. A. (1983). Pharmacokinetics in the aged. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Pharmacologic aspects of aging. St. Louis, MO: C. V. Mosby.
175. Robinson, D. S., Roberts, D. L., Smith, J. M., Stringfellow, J. c., Kaplita, S. B., Seminara, J. A., & Marcus, R. N. (1996). The safety profile of nefazodone. lournal of Clinical Psychiatry, 57(Suppl. 2), 31-38.
176. Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research and Brain Research Reviews, 18, 247-291.
177. Roose, S. P., & Glassman, A. H. (1994). Antidepressant choice in the patient with cardiac disease: Lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. lournal of Clinical Psychiatry, 55(Suppl. A), 83-87.
178. Rose, E., Levin, E. D., Behm, F. M., Adivi, C., & Schur, C. (1990). Transdermal nicotine facilitates smoking cessation. Clinical Pharmacology & Therapeutics, 47, 323-330.
179. Ryder, M. A. (1993). Peripherally inserted central venous catheters. Nursing Clinics of North America, 28, 937-971.
180. Sachdev, P. (1995). The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophrenia Bulletin, 21, 431-449.
181. Sachdev, P. (1995). The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophrenia Bulletin, 21, 451-461.
182. Schmidt, C. J., Sorensen, S. M., Kehne, J. H., Carr, A. A., & Palfreyman, M. G. (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sciences, 56, 2209-2222.
183. Schneider, J. K., Mion, L. C., & Frengley, J. D. (1992). Adverse drug reactions in an elderly outpatient population. American Journal of Hospital Pharmacy, 49, 90-96.
184. Schneider, P., Gift, M. G., Lee, Y. P., Rothermich, E. A., & Sill, B. E. (1995). Cost of medication-related problems at a university hospital. American Journal of Health-System Pharmacology, 52, 2415-2418.
185. Schumock, G. T., & Thornton, P. (1992). Focusing on the preventability of adverse drug reactions. Hospital Pharmacy, 27, 538.
186. Segraves, R. T. (1995). Antidepressant-induced orgasm disorder. Journal of Sex & Marital Therapy, 21, 192-201.
187. Sharma, H., & Pompei, P. (1996). Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies. Drugs & Aging, 8, 430-435.
188. Sheiner, L. B., Benet, L. Z., & Pagliaro, L. A. (1981). A standard approach to compiling clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics, 9, 59-127.
189. Slattery, R., Nelson, S. D., & Thummel, K. E. (1996). The complex interaction between ethanol and acetaminophen. Clinical Pharmacology & Therapeutics, 60, 241-246.
190. Smiley, R. M., & Finster, M. (1996). Do receptors get pregnant too? Adrenergic receptor alterations in human pregnancy. Journal of Maternal-Fetal Medicine, 5, \06-114.
191. Smith, M., & Buckwalter, K. C. (1992). Medication management, antidepressant drugs, and the elderly: An overview. Journal of Psychosocial Nursing and Mental Health Services, 30(10), 30-36.
192. Stahl, S. M. (1992). Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacology Bulletin, 28, 3-9.
193. Stahl, S. (1994). 5HTlA receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to mechanism of action of antidepressant drugs? Psychopharmacology Bulletin, 30, 39-43.
194. Stanton, J. M. (1995). Weight gain associated with neuroleptic medication: A review. Schizophrenia Bulletin, 21, 463-472.
195. Steward, D. (1993). Eutectic mixture of local anesthetics (EMLA): What is it? What does it do? Journal of Pediatrics, 22(5, Part 2), S21-S23.
196. Stolley, P. D. (1990). How to interpret studies of adverse drug reactions. Clinical Pharmacology & Th erapeutics, 48, 337-339.
197. Stowe, C. D., Ivey, M. M., Kuhn, R. L., & Piecoro, L. (1995). Administering intravenous drugs to infants and children. In L. A. Pagliaro & A. M. Pagliaro (Eds.), Problems in pediatric drug therapy (3rd ed., pp. 541-675). Hamilton, IL: Drug Intelligence.
198. Taddio, A., Nulman, I., & Reid, E. (1992). Effect of lidocaine-prilocaine cream (EMLA®) on pain of intramuscular Fluzone® injection. Canadian Journal of Hospital Pharmacy, 45, 227-230.
199. Taddio, A., Robieux, I., & Koren, G. (1992). Effect of lidocaine-prilocaine cream on pain from subcutaneous injection. Clinical Pharmacy, 11, 347-349.
200. Tatro, D. S. (1991). Food-drug interactions-Part I. Facts and Comparisons Drug Newsl etter, 10(6), 41-42.
201. Tatro, D. S., Ow-Wing, S. D., & Huie, D. L. (1986). Drug toxicity. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 180-187). St Louis, MO: C. V. Mosby.
202. Taylor, D. P., Carter, R. B., Eison, A. S., Mullins, V. L., Smith, H. L., Torrente, R., Wright, R. N., & Yocca, F. D. (1995). Pharmacology and neurochemistry of nefazodone, a novel antidepressant. Journal of Clinical Psychiatry, 56(Suppl. 6), 3-11.
203. Taylor, D., & Lader, M. (1996). Cytochromes and psychotropic drug interactions. British Journal of Psychiatry, 168, 529-532.
204. Thomas, N. R. (1986). Review of the anatomy, physiology, and assessment of the central nervous system. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Pharmacologic aspects of nursing (pp. 207-222). St. Louis, MO: C. V. Mosby.
205. Thomson, P. D., Rowland, M., & Melmon, K. L. (1971). The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. American Heart Journal, 82, 417-421.
206. Toth, P., & Frankenburg, F. R. (1994). Clozapine and seizures: A review. Canadian Journal of Psychiatry, 39, 236-238.
207. Veda, C. T., & Hoie, E. B. (1995). Pediatric pharmacokinetics. In A. M. Pagliaro & L. A. Pagliaro (Eds.), Problems in pediatric drug therapy (3rd ed., pp. 713-735). Hamilton, IL: Drug Intelligence.
208. Varhe, A., Olkkola, K. T., & Neuvonen, P. (1994). Pharmacokinetics and drug disposition: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology & Therapeutics, 56, 601-607.
209. Volpicelli, R., Alterman, A. I., & Hayashida, M. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876-880.
210. Watsky, E., & Salzman, C. (1991). Psychotropic drug interactions. Hospital and Community Psychiatry, 42, 247-256.
211. Weiner, M., & Weiner, G. (1996). The kinetics and dynamics of responses to placebo. Clinical Pharmacology & Therapeutics, 60, 247-254.
212. Williams, L., Davis, A., & Lowenthal, D. T. (1993). The influence of food on the absorption and metabolism of drugs. Medical Clinics of North America, 77, 815-829.
213. Yee, G. c., Stanley, D. L., Pessa, L., Dalla Costa, T., & Beltz, S. E. (1995). Effect of grapefruit juice on blood cyclosporin concentration. Lancet, 345, 955-956.
214. Yee, L. Y, & Lopez, R. (1992). Transdermal fentanyl. Annals of Pharmacotherapy, 26, 1393-1399.
215. Zaleon, C. R., & Guthrie, S. K. (1994). Antipsychotic drug use in older adults. American Journal of Hospital Pharmacy, 51, 2917-2943.
216. Zimmer, R., Gieschke, R., Fischbach, R., & Gasic, S. (1990). Interaction studies with moclobe-mide. Acta Psychiatrica Scandinavica, 360, 84-86.